|
|
 |
|
Viewing report
|
|
|
|
Adult and Adolescent Vaccines Market to 2017 - Partnerships Increase as Licensing and Co-Development Account for 73% of all Deal-Making Activity in 2010
GBI Research, Aug 2011, Pages: 118
“Adult and Adolescent Vaccines Market to 2017 – Partnerships Increase as Licensing and Co-Development Account for 73% of all Deal-Making Activity in 2010”, which provides insights into the global vaccines market, forecast until 2017. The report provides an in-depth analysis of five vaccines, which include pneumococcal, seasonal flu, human papillomavirus, hepatitis A and hepatitis B. The report also examines the immunization schedules for the covered vaccines. In addition, the report also includes insights into the vaccines R&D pipeline.
The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by a team of industry experts.
This analysis shows that the overall global vaccines market was valued at $28 billion in 2010. The market is expected to witness growth at a CAGR of 11.5% for the forecast period, and will reach $56.7 billion by 2017. The global market revenues are expected to increase due to the introduction of new molecules which are currently in the regulatory filing stage, and those in the later stages of development. The top pharmaceutical companies in the vaccines market are GlaxoSmithKline, Sanofi, Pfizer, Novartis AG., Merck & Co. Inc, and SP-MSD. Approximately 88% of the market is covered by these six companies.
Scope
- Data and analysis on the global adult and adolescent vaccines market
- Annualized market data for the adult and adolescent vaccines market from 2007 to 2017 for pneumococcal vaccines, human pappilomavirus vaccines, seasonal flu vaccines, hepatitis A vaccines and hepatitis B vaccines
- Key drivers and restraints that have had a significant impact on the market
- The competitive landscape of the global vaccines market
- Key M&A activities, licensing agreements and co-development deals that took place in the vaccines market between 2009 and 2011.
Reasons to buy
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
- Devise a more tailored country strategy through the understanding of key drivers and barriers of the vaccines market.
- Develop key strategic initiatives by understanding the key focus areas and leading companies.
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
